TNDM vs. DXCM

In the year-to-date period, TNDM achieves a -0.64% return, which is significantly lower than DXCM's 1.80% return. Over the past 10 years, TNDM has underperformed DXCM with an annualized return of -12.26%, while DXCM has yielded a comparatively higher 18.36% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Tandem Diabetes Care, Inc. (TNDM) and DexCom, Inc. (DXCM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current TNDM Sharpe Ratio is 0.52, which is higher than the DXCM Sharpe Ratio of -0.71. The chart below compares the historical Sharpe Ratios of TNDM and DXCM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither TNDM nor DXCM has paid dividends to shareholders.

The maximum TNDM drawdown since its inception was -99.25%, roughly equal to the maximum DXCM drawdown of -94.61%. Use the drawdown chart below to compare losses from any high point for TNDM and DXCM. For additional features, visit the drawdowns tool.

Tandem Diabetes Care, Inc. (TNDM) has a higher volatility of 12.58% compared to DexCom, Inc. (DXCM) at 9.96%. This indicates that TNDM's price experiences larger fluctuations and is considered to be riskier than DXCM based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Tandem Diabetes Care, Inc. and DexCom, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.